Blood
Articles in this Issue
The allogeneic fully human anti-CD38-CAR-γδ T cells enable off-the-shelf CAR-T cell therapy for myeloma
Abstract Introduction The prognosis for myeloma patients has been improved by proteasome inhibitors (PIs), immunomodulat...
Association between inflammatory and hemolysis markers in children with sickle cell disease
Abstract Background: Sickle cell disease (SCD) is a severe hemoglobin disorder characterized by recurrent vaso-occlusive events, chronic hem...
Amx-883, a potent and selective degrader of BRD9 drives differentiation in acute myeloid leukaemia and shows synergistic efficacy in combination with venetoclax In Vivo and prevents the emergence of resistance to venetoclax in vitro.
Abstract Background: Acute Myeloid Leukaemia (AML) is commonly characterized by a differentiation block which prevents maturation and result...
Central nervous system disease status significantly impacts survival in pediatric acute myeloid leukemia: A report from Children's Oncology Group study AAML1831
Abstract Introduction: Standard treatment of pediatric AML (in contrast to adult AML) includes diagnostic lumbar puncture (LP) and intrathec...
Functional plasma cell signatures mark AML chemotherapy responders: Evidence from immune niche profiling
Abstract Chemoresistance, primarily driven by leukemic stem cells (LSC), remains a major challenge in the treatment of acute myeloid leukemi...
Randomized comparison between isatuximab-rd versus rd induction, followed by isa-R versus R maintenance in very elderly patients with NDMM: Efficacy data on MRD after induction (AGMT-MM04 Trial)
Abstract Introduction In very elderly newly diagnosed pts with multiple myeloma, data comparing induction treatment with Isatuximab plus len...
Venetoclax plus azacitidine vs. traditional chemotherapy in younger patients with Acute Myeloid Leukemia: A single-center real-world study
Abstract Objective: To compare the efficacy and safety of venetoclax plus azacitidine (V+A) versus traditional “3+7” chemotherapy as first-l...
Unveiling the “second wave”: Viral-triggered biphasic CAR-T expansion drives late-onset IEC-HS: Characterization and successful management
Abstract Background: While cytokine release syndrome (CRS) and ICANS are well-defined acute toxicities of CAR-T cell therapy, the landscape...
Monoclonal antibodies against pathogenic S100A8/9 alarmins can restore hematopoiesis and result in immunomodulation in myelodysplasia and leukemia models
Abstract Introduction: Myelodysplastic syndromes (MDS); chronic myelomonocytic leukemias (CMML) and acute myeloid leukemia (AML) are charact...
Small molecule OTS167 increases erythropoiesis and improves anemia in diamond blackfan anemia models in vitro and In Vivo
Abstract Diamond Blackfan Anemia (DBA) is a rare inherited bone marrow failure syndrome characterized by anemia, congenital anomalies, and a...
Improved graft-versus-host-disease/relapse free survival due to reduced relapse rate and acute gvhd with pharmacokinetics-guided busulfan conditioning regimen for allogeneic stem cell transplantation in adult patients with myeloid hematologic malignancies
Abstract Introduction Busulfan represents a cornerstone of conditioning regimen employed before allogeneic stem cell transplantation (Allo-S...
Financial and clinical implications of xromi as a new commercial liquid formulation of hydroxyurea
Abstract Background: Hydroxyurea is now firmly the standard of care for children with sickle cell disease (SCD) beginning early in life, res...
Safety of live-attenuated MMR vaccination in patients with multiple myeloma receiving daratumumab after autologous stem cell transplantation
Abstract Introduction: Antibodies for vaccine-preventable infections are significantly reduced after autologous stem cell transplantation (A...
Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM)
Abstract Introduction: Cilta-cel is a BCMA-directed CAR T-cell therapy that has shown remarkable efficacy in patients with RRMM. As real-worl...
Complement inhibitor use is not a significant predictor of cancer incidence: A real-world study of patients requiring chronic complement blockade.
Abstract Complement inhibitors (CI) are the mainstay therapy for classic complement-mediated disorders including paroxysmal nocturnal hemogl...
Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia
Abstract Background Genetic markers like 17p deletion (del17p), TP53 mutation (TP53m), and immunoglobulin heavy variable chain (IGHV) mutatio...
Oncogeriatric assessment of patients with chronic lymphatic leukaemia over 65 years old undergoing target therapies: A pilot study conducted at the fondazione policlinico gemelli.
Abstract Introduction: Chronic lymphocytic leukemia (CLL) is a common haematological neoplasm in elderly patients (pts), with a median age a...
Efficacy of early single low dose of rituximab in prophylaxis of EBV reactivation and EBV related post-transplant lymphoproliferative disorder after allogeneic hematopoietic cell transplantation
Abstract Introduction: Reactivation of Epstein-Barr virus (EBV) is common in allogeneic hematopoietic cell transplantation(allo-HCT). EBV re...
An international view on the current approaches to frontline chronic lymphocytic leukemia therapy
Abstract Background: The treatment landscape for chronic lymphocytic leukemia (CLL) has evolved significantly in recent...
Real-world experience with apheresis for gene therapy in transfusion-dependent β-thalassemia: The largest single-center report
Abstract Introduction CRISPR-Cas9 based gene therapy has been the first cellular therapy approved in the UK since September 2024 for the tre...
Effectiveness of belumosudil in acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT): A real-world observational study
Abstract Background: Acute graft-versus-host disease (aGVHD) remains a major barrier to successful allogeneic hematopoietic stem cell transp...
Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis
Abstract TP53 alterations (including mutations and/or deletions) are among the most adverse genomic events in hematological malignancies, ob...
Mortality patterns due to aplastic anemia in the United States: A retrospective analysis from 1999 to 2023
Abstract Introduction: Aplastic anemia (AA), a life-threatening bone marrow failure disorder with an incidence of 0.6-6....
MAP2K1 and MAP2K2 genes alterations in hairy cell leukemia and hairy cell leukemia variant.
Abstract Background: Hairy cell leukemia (HCL) is an indolent B-cell neoplasm characterized by the expression of CD20, CD22, CD25, CD11c, CD1...
Cooperative activation of NF-κB by inv(3)/t(3;3) and NRAS mutations drives myeloid leukemogenesis
Abstract In acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), inversion/translocation of chromosome 3 (inv(3)/t(3;3)) is a r...